Search
Betrixaban
go.drugbank.com/drugs/DB12364ApprovedIt was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. … VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].
Categories: P-glycoprotein substratesDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalDelandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.
Sulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalSulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Trazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigationalTrazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyc...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: Ag-trazodone, Nu-trazodone-D - Tab 150mgAcetic acid C-11
go.drugbank.com/drugs/DB15111InvestigationalAcetic acid C-11 is under investigation in clinical trial NCT01953965 (Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and
Itraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigationalFirst synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections. It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each posses...
Synonyms: (±)-1-SEC-BUTYL-4-(P-(4-(P-(((2R*,4S*)-2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONECategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedIt present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA.
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalDecreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine [A32042]. … The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions [A32046
Synonyms: D6 tetrabenazine, D6-tetrabenazineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates